Onkologische Erkrankungen

  • Jürgen Sökeland
  • Angelika Sökeland
Chapter

Zusammenfassung

Bei onkologischen Erkrankungen der Urogenitalorgane erfolgt die tumorspezifische Behandlung durch Operation, Bestrahlung, Chemotherapie sowie bei einigen Tumoren durch Hormonabsenkung und/oder Immuntherapie.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adlercreutz H, Markkanen H, Watanabe S (1993) Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342:1209–1210PubMedCrossRefGoogle Scholar
  2. Adlercreutz H, Höckerstedt K, Bannwart C (1977) Effect of dietary components, including lignans and phytoestrogens, an enterohepatic circulation and liver metabolism of estrogens and an sex hormon binding globulin (SHBG).J Steroid Biochem 27:1135–1144CrossRefGoogle Scholar
  3. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels. Cancer Causes Control 11: 847–852PubMedCrossRefGoogle Scholar
  4. Altwein J (1997) Mit Phytoöstrogenen gegen Krebs. DAZ 137:4667–4670Google Scholar
  5. Anderson JW, Johnstone BM, Cook-Newel I ME (1995) Metaanalysis of the effects of soy protein intake and serum lipids. N Engl J Med 333:276–282PubMedCrossRefGoogle Scholar
  6. Armanini D, Bonanni G, Palermo M (1999) Reduction of serum testosterone in men by licorice. N Engl J Med 341:1158PubMedCrossRefGoogle Scholar
  7. Aronson WJ, Tymchuk CN, Elashoff RM, McBride WH, McLean C, Wang H, Heber D (1999) Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer 35:130–136PubMedCrossRefGoogle Scholar
  8. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G (2001) A meta-analysis of alcohol drinking and cancer risk. Br J Cancer 85:1700–1705PubMedCrossRefGoogle Scholar
  9. Bairati I, Meyer F, Fradet Y, Moore L (1998) Dietary fat and advanced prostate cancer. J Urol 159:1271–1275PubMedCrossRefGoogle Scholar
  10. Beuth J (2000) Unconventional cancer therapy on trial. Mistletoe preparations: only effective in the test tube? MMW Fortschr Med 142:14PubMedGoogle Scholar
  11. Beuth J, Moss RW (2000) Wissenschaftlich begründete komplementäre Therapiemaßnahmen in der Onkologie. Z Onko / J of Oncol 32:2Google Scholar
  12. Beuth J, Ko HL, Tunggal L, Gabius HJ, Steuer M, Uhlenbruck G, Pulverer G (1993) Das Lektin in der Mistel in der adjuvanten Therapie beim Mammakarzinom — erste klinische Erfahrungen. Medwelt 44:217–220Google Scholar
  13. Blumenfeld AJ, Fleshner N, Casselman B, Trachtenberg J (2000) Nutritional aspects of prostate cancer: a review. Can J Urol 7:927–935PubMedGoogle Scholar
  14. Bouffioux Ch, Kurth KH, Bono A, Oosterlinck W, Boeken Kruger C, de Pauw M, Sylvester R, and the members of the European Organization for Research and Treatment of Cancer Genitourinary Group (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 153:934–941PubMedCrossRefGoogle Scholar
  15. Brosman SA (1982) Experience with bacillus Calmette-Guerin in patients with superficial bladder cancer. Urology 128:27Google Scholar
  16. Clark LC, Dalkin B, Krongrad A et al. (1998) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 81:730–734PubMedCrossRefGoogle Scholar
  17. Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH (2000) Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians’ Health Study. Cancer Causes Control 11:617–626PubMedCrossRefGoogle Scholar
  18. Corder EH, Guess HA, Hulka BS et al. (1993) Vitamin D and prostate cancer: a predi-agnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467–472PubMedGoogle Scholar
  19. De la Taille A (2001) PC SPES in prostatic cancer: critical review of the. Prog Urol 11:428–432PubMedGoogle Scholar
  20. Dennis LK, Dawson DV (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13:72–79PubMedCrossRefGoogle Scholar
  21. DiPaola RS, Zhang H, Lambert GH et al. (1998) Clinical and biological activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 339: 785–791PubMedCrossRefGoogle Scholar
  22. Fair WR (1999) Back to the future — The role of complementary medicine in urology. J of Urol 162:411–420CrossRefGoogle Scholar
  23. Fair WR, Fleshner NE, Heston W (1997) Cancer of the prostate: a nutritional disease? Urology 50:840–848PubMedCrossRefGoogle Scholar
  24. Fawzy Fl, Fawzy N, Hyuns P et al. (1990) Malignant melanoma: effects of an early structured psychiatiric intervention, coping, and affective state an recurrence and survival six years later. Arch Gen Psychiatry 50:681–689CrossRefGoogle Scholar
  25. Fleischhauer AT, Arab L (2001) Garlic and cancer: A critical review of the epidemiologice. J Nutr 131:1032 S–1040 SGoogle Scholar
  26. Fradet Y, Meyer F, Bairati I, Shadmani R, Moore L (1999) Dietary fat and prostate cancer progression and survival. Eur Urol 35:388–391PubMedCrossRefGoogle Scholar
  27. Freeman VL, Meydani M, Yong S, Pyle J, Wan Y, Arvizu-Durazo R, Liao Y (2000) Prostatic levels of tocopherols, carotenoids, and retinol in relation to plasma levels and self-reported usual dietary intake. Am J Epidemiol 151:109–118PubMedCrossRefGoogle Scholar
  28. Friedenreich CM, Thune I (2001) A review of physical activity and prostate cancer risk. Cancer Causes Control 12:461 – 475PubMedCrossRefGoogle Scholar
  29. Gerdes K (1986) Der Sturz aus der normalen Wirklichkeit und die Suche nach dem Sinn. Ein sozialwissenschaftlicher Beitrag zu Fragen der Krankheitsverarbeitung bei Krebskranken. In: Schmidt W (Hrsg) Jenseits der Nonnalität — Leben mit Krebs. Kaiser, MünchenGoogle Scholar
  30. Giovannucci E (1999) Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologice. J Natl Cancer Inst 91:317–331PubMedCrossRefGoogle Scholar
  31. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC (2002) A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94: 391–398PubMedCrossRefGoogle Scholar
  32. Goebell P, Otto T, Suhr J, Rübben H (2002) Evalutation of unconventional treatment modality with mistle toe lectin to prevent recurrence of superficial bladder cancer. J Urol 168:72–75PubMedCrossRefGoogle Scholar
  33. Goepel M, Rübben H (1991) Adjuvant therapy in renal cancer. World J Urol 9:232–236CrossRefGoogle Scholar
  34. Graham S, Haughey B, Marshall J, Priore R, Byers T, Rzepka T, Mettlin C, Pontes JE (1983) Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst 70:687–692PubMedGoogle Scholar
  35. Greer S, Moorey S, Watson M (1989) Patients adjustment to cancer: the Mental Adjustment to Cancer (MAC) Scale vs. clinical ratings. J Psychosomat Res 33:373–377CrossRefGoogle Scholar
  36. Griffiths K, Khoury S (1994) Primer on molecular control of prostatic growth.Scientific Communications International, JerseyGoogle Scholar
  37. Griffiths K, Denis L, Turkes A, Morton MS (1998) Possible relationship between dietary factors and pathogenesis of prostate cancer. Int J Urol 5:195–213PubMedCrossRefGoogle Scholar
  38. Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3.J Urol 159:2035–2039PubMedCrossRefGoogle Scholar
  39. Haenszel W, Kurihara M (1968) Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40:43–68PubMedGoogle Scholar
  40. Hajto T, Lanzrein C (1986) Natural killer and antibody-dependent cell-mediated cyto-toxity activities and large granular lymphocyte frequencies in viscum album-treated breast cancer patients. Oncology 43:93–97PubMedCrossRefGoogle Scholar
  41. Hajto T, Hostanska K, Gabius HJ (1989) Modulatory potency of the b-galactoside-spe-cific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 49:4803–4808PubMedGoogle Scholar
  42. Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ (1990) Increased secretion of tumor necrosis factor a, interleukin 1, and interleukin 6 by human mononuclear cells exposed to b-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 50:3322–3326PubMedGoogle Scholar
  43. Hajto T, Hostanska K, Fischer J, Lentzen H (1996) Investigations of cellular parameters to establish the response of a biomodulator: galactoside-specific lectin from viscum album plant extract. Phytomedicine 3:129–137PubMedCrossRefGoogle Scholar
  44. Hammar M, Frisk J, Grimas O, Hook, M, Spetz AC, Wyon Y (1999) Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: A pilot study. J Urol 161:853–856PubMedCrossRefGoogle Scholar
  45. Hartman TJ, Albanes D, Pietinen P, Hartman AM, Rautalahti M, Tangrea JA, Taylor PR (1998) The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 7:335–340PubMedGoogle Scholar
  46. Hauser SP (1990) Iscador für die Krebsbehandlung: Analyse klinischer Untersuchungsergebnisse. In: Jungi WF, Senn HJ (Hrsg) Krebs und Alternativmedizin II. Springer, Berlin Heidelberg New York Tokyo, S 88–96CrossRefGoogle Scholar
  47. Heinonen OP, Albanes D, Virtamo J (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440–446PubMedCrossRefGoogle Scholar
  48. Heiny BM (1991) Additive Therapie mit standardisiertem Mistelextrakt produziert die Leukopenie und verbessert die Lebensqualität von Patientinnen mit fortgeschrittenem Mammakarzinom unter palliativer Chemotherapie (VEC-Schema). Krebsmedizin 12Google Scholar
  49. Heiny B, Beuth J (1994) Das Lektin der Mistel als Immunmodulator: Effektorwirkung auf b-Endorphin- and Zytokinfreisetzung bei Mammakarzinompatientinnen. Dtsch Z Onkol 26:291–293Google Scholar
  50. Heiny BM, Albrecht V, Beuth J (1998) Lebensqualitätsstabilisierung durch Mistellektin-1 normierten Extrakt beim fortgeschrittenen kolorektalen Karzinom. Onkologie 4 [Suppl 1]: 35–39CrossRefGoogle Scholar
  51. Hsieh T, Chen SS, Wang X, Wu JM (1997) Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem Mol Biol Int 42:535–544PubMedGoogle Scholar
  52. Jacobsen BK, Knutsen SF, Fräser GE (1998) Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study. Cancer Causes Control 9:553–557PubMedCrossRefGoogle Scholar
  53. Jain MG, Hislop GT, Howe GR, Ghadirian P (1999) Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. Nutr Cancaer 34: 173–184CrossRefGoogle Scholar
  54. Kalden M, Wiesenauer M (1994) Immuntherapie. In: Dittmar FW, Loch EG, Wiesenauer M (Hrsg) Naturheilverfahren in der Frauenheilkunde und Geburtshilfe. Hippokrates, Stuttgart, S 287–288Google Scholar
  55. Kayser K, Gabius S, Hagemeyer O (1992) Analysis of tumor necrosis factor a-specific, lactose-specific and mistletoe lectin-specific binding sites in human lung carcinomas by labelled ligands. Virchows Archiv A Pathol Anat 421:345–349CrossRefGoogle Scholar
  56. Keller J (1954) Urologie. Ein Leitfaden für den Urologen und den urologisch interessierten Praktiker In: Fromme A, Grote LR, Lange F, Naujoks HD (Hrsg) Medizinische Praxis. Steinkopff, Dresden (Sammlung für die medizinische Fortbildung, Bd 37)Google Scholar
  57. Kjaer M (1988) Misteltenbehandling of metataserende nyrecancer. En fase II under-sogelse. Ugeskr Laeger 150:1923–1928PubMedGoogle Scholar
  58. Klebingat KJ (1998) Unkonventionelle alternative Therapieverfahren in der Palliativen urologischen Onkologie. Urologe B 38:249–251CrossRefGoogle Scholar
  59. Kleijnen J, Knipschild P (1994) Misteltoe treatment for cancer. Review of controlled trials in humans. Phytomedicine 1:255–260PubMedCrossRefGoogle Scholar
  60. Kraft K (2000) Phytotherapie.Thieme, StuttgartGoogle Scholar
  61. Krege S, Giani G, Meyer T et al. (1996) A randomized trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus Bacillus Calmette-Guerin. Urology 156:962CrossRefGoogle Scholar
  62. Küchler T, Henne-Bruns D, Rappat S et al. (1999) Impact of psychotherapeutic support an gastrointestinal cancer patients undergoing surgery: survival results of a trial. Hepatogastroenterology 46/25:322–335PubMedGoogle Scholar
  63. Kucuk O, Sarkar FH, Sakr W et al. (2001) Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10:861–868PubMedGoogle Scholar
  64. Lamm DL, van der Meijden PM, Morales A et al. (1992) Incidence and treatment of complications of Bacillus Calmette Guerin intravesical therapy in superficial bladder cancer. Urology 147:596Google Scholar
  65. Lamm DL et al.(1994) Megadose vitamins in bladder cancer. A doubble blind clinical trias.J Urol 151:21–26Google Scholar
  66. Leroi R (1975) Klinische Erfahrungen mit dem Mistelpräparat Iscador. In: Wolff O (Hrsg) Die Mistel in der Krebsbehandlung. Klostermann, Frankfurt, S 67–70Google Scholar
  67. Madaus G (1938) Lehrbuch der biologischen Heilmittel. Olms, HildesheimGoogle Scholar
  68. Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L (1999) Dietary fat and prostate cancer survival. Cancer Causes Control 10:245–251PubMedCrossRefGoogle Scholar
  69. Morton MS, Matos-Ferreira A, Abranches-Monteiro L et al. (1997) Measurement and metabolism of isoflavonoids and lignans in the human male. Cancer Lett 114: 145–151PubMedCrossRefGoogle Scholar
  70. Moyad MA, Hathaway S, Ni HS (1999a) Traditional Chinese medicine, acupuncture, and other alternative medicines for prostate cancer: an introduction and the need for more research.. Semin Urol Oncol 17:103–110PubMedGoogle Scholar
  71. Moyad MA, Pienta KJ, Montie JE (1999b) Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urology 54:319–323PubMedCrossRefGoogle Scholar
  72. Muir CS, Nectoux J, Staszewski J (1991) The epidemiology of prostatic cancer: geographical distribution and timetrends. Acta Oncol 30:133–140PubMedCrossRefGoogle Scholar
  73. Omenn GS, Goodman GE, Thornquist MD et al. (1996) Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88:1550–1559PubMedCrossRefGoogle Scholar
  74. Otto T, Lümmen G, Bex A, Suhr J, Raz A, Rübben H (2002) Tumorcell motility/as novel target in cancer. Onkologie 25:172–177PubMedCrossRefGoogle Scholar
  75. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MKB, Bijnens L for the Members of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on superficial bladder cancer (1996) A combined analysis of European Organization for Research and Treatment of Cancer, and medical research council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 156:1934–1941PubMedCrossRefGoogle Scholar
  76. Pfeifer BL, Pirani JF, Hamann SR, Klippel KF (2000) PC-SPES, a dietary supplement for the treatment of hormonerefractory prostate cancer. BJU Int 85:481–485PubMedCrossRefGoogle Scholar
  77. Rafi MM, Rosen RT, Vassil A, Ho CT, Zhang H, Ghai G, Lambert G, DiPaola RS (2000) Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavo-noid. Anticancer Res 20:2653–2658PubMedGoogle Scholar
  78. Rafi MM, Vastano BC, Zhu N, Ho CT, Ghai G, Rosen RT, Gallo Ma DiPaola RS (2002) Novel polyphenyl molecule isolated from licirice root (glycrrhia glabra) induces apop-tosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. J Agric Food Chem 50:677–684PubMedCrossRefGoogle Scholar
  79. Roeder G (1978) Mitteilungen aus der Behandlung mit Viscum album. Zur Iscador-Behandlung des Prostatacarzinoms. Verein für Krebsforschung, Ariesheim und Stuttgart, S 13Google Scholar
  80. Schmitz-Dräger BJ, Eichholzer M, Beiche B, Ebert T (2001) Nutrition and prostate cancer. Urol Int 67:1–11PubMedCrossRefGoogle Scholar
  81. Schröder FH, Kranse R, Dijk MA, Blom JM, Tijburg LM, Weststrate JA, Dagnelie PC (2000) Tertiary prevention of prostatic cancer by dietary intervention: results of a randomized, doubleblind, placebo controlled cross-over study. Eur Urol 37 [Suppl 2]: 24CrossRefGoogle Scholar
  82. Schwab ED, Normolle D, Pacis RA, Cho SS, Pienta KJ (1998) A high-fat diet does not influence the growth of the Dunning R3327-H transplantable prostate adenocarcinoma. Anticancer Res 18:3603–3607PubMedGoogle Scholar
  83. Schwabe U, Paffrath D (2000) Arzneiverordnungsreport 1999. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  84. Severson RK, Nomura AM, Grove JS, Stemmermann GN (1989) A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 49:1857–1860PubMedGoogle Scholar
  85. Sommer F, Peters C, Klotz T, Michna H, Schoenenberger A, Engelmann U (2002) Sport und Bewegung in der Prävention Urologischer Erkrankungen. Urologe BGoogle Scholar
  86. Spiegel D, Bloom JR, Kraemer HC, Gottheil E (1989) Effect of psychosocial treatment an survival of patients with metastatic breast cancer. Lancet 14:888–891CrossRefGoogle Scholar
  87. Tiwari RK, Geliebter J, Garikapaty VR, Yedavelli SP, Chen S, Mittelman A (1999) Antitumor effects of PC-SPES, an herbal formulation in prostate cancer. Int J Oncol 14: 713–719PubMedGoogle Scholar
  88. Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM (2000) Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. J Urol 163:187–190PubMedCrossRefGoogle Scholar
  89. Wagner H, Wiesenauer M (1995) Phytotherapie.G.Fischer, StuttgartGoogle Scholar
  90. Watzl B, Leitzmann C (1999) Bioaktive Substanzen in Lebensmitteln, 2. Aufl. Hippokrates, StuttgartGoogle Scholar
  91. Wynder EL, Fair WR (1996) Editorial: prostate cancer-nutrition adjunct therapy. J Urol 156:1364PubMedCrossRefGoogle Scholar
  92. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E (1998) Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90:1219–1224PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Jürgen Sökeland
    • 1
  • Angelika Sökeland
    • 1
  1. 1.HerdeckeDeutschland

Personalised recommendations